Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Net Cash Flow: 2011-2024

Historic Net Cash Flow for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $51.8 million.

  • Adma Biologics' Net Cash Flow fell 1780.29% to -$28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.3 million, marking a year-over-year decrease of 301.77%. This contributed to the annual value of $51.8 million for FY2024, which is 247.27% up from last year.
  • As of FY2024, Adma Biologics' Net Cash Flow stood at $51.8 million, which was up 247.27% from -$35.2 million recorded in FY2023.
  • Over the past 5 years, Adma Biologics' Net Cash Flow peaked at $51.8 million during FY2024, and registered a low of -$35.2 million during FY2023.
  • For the 3-year period, Adma Biologics' Net Cash Flow averaged around $17.4 million, with its median value being $35.4 million (2022).
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 833.30% in 2022, then tumbled by 199.26% in 2023.
  • Adma Biologics' Net Cash Flow (Yearly) stood at $29.2 million in 2020, then plummeted by 116.57% to -$4.8 million in 2021, then surged by 833.30% to $35.4 million in 2022, then plummeted by 199.26% to -$35.2 million in 2023, then soared by 247.27% to $51.8 million in 2024.